T. gondii, Schizophrenia, and other Psychiatric Disorders
Powerful evidence supports an association between the parasite Toxoplasma gondii and schizophrenia.
Risks of Marijuana
The combination of a large selection of products, poor labeling, and a lack of regulatory oversight in the states that have approved marijuana for recreational use has created a potentially dangerous situation for consumers, who receive little guidance regarding dosing.
Antipsychotics in Dementia: Quantifying the Mortality Risk
Antipsychotics are associated with an increase in mortality risk for patients with dementia. Alternative interventions should be considered first to treat agitation, aggression, and psychosis in this population
Schizophrenia Patients with Genetic Mutation Have Equal Response but More Serious Side Effects; Passage of Medical Marijuana Laws Does Not Increase Adolescent Use
Compromised Health in Schizophrenia: Venous Thromboembolism and Fractures
Patients with schizophrenia have an elevated risk of venous thromboembolism and fractures.
About Alan J. Gelenberg, M.D.
Alan J. Gelenberg, M.D. is a Professor Emeritus at the University of Arizona and has chaired Departments of Psychiatry at Arizona and Penn State. He has also been on the faculty of Harvard Medical School, MIT, and the University of Wisconsin. He is Editor-in-Chief of the Journal of Clinical Psychiatry, the field's most widely read peer-reviewed journal, and founding author of Biological Therapies in Psychiatry Newsletter.
Dr. Gelenberg has been lead author of manuscripts in the Lancet, New England Journal of Medicine, and Journal of the AMA and has published over 280 scientific articles, editorials, and book chapters. He chaired the American Psychiatric Association's (APA) workgroup on Treatment Guidelines for Major Depressive Disorder, 3rd edition, was on a joint APA/AMA taskforce on similar guidelines for primary care and a committee to advise the U.S. Centers for Disease Control about depression. He helped create the ASEX scale to monitor sexual side effects of antidepressants and electronic versions of suicide-assessment instruments.
Often a guest lecturer and visiting professor throughout the world, Dr. Gelenberg has sat on National Institute of Mental Health committees, is a Distinguished Life Fellow of the APA, former chair of its Committee on Research on Psychiatric Treatments, past President of the West Coast College of Biological Psychiatry, fellow of the American College of Neuropsychopharmacology, and member of the American College of Psychiatrists. He is on the Council of the Central Pennsylvania Psychiatric Society, Boards of Directors of the American Society of Clinical Psychopharmacology and the Pennsylvania Psychiatric Institute, Professional Advisory Council of the Neuroleptic Malignant Syndrome Information Service, Scientific Advisory Board of the Depression and Bipolar Support Alliance, and NCDEU Steering Committee. He chairs the Data and Safety Monitoring Board of the NIMH study Treating Depression and Insomnia (TRIAD). Consistently listed in The Best Doctors in America and America's Top Doctors, he received an Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill and two teaching awards at the University of Arizona. He has mentored numerous researchers, many of whom are now highly productive scientists.
A native of Philadelphia, Alan Gelenberg received an A.B. from Columbia University and M.D. from the University of Pennsylvania. After a year's internship in internal medicine at Presbyterian-University of Pennsylvania Medical Center, he was a resident in psychiatry at the Massachusetts General Hospital. For six years he was a commissioned officer in the U.S. Army Reserves. Dr. Gelenberg's wife was the first woman TV news anchor in Arizona, on the air for 34 years, and a candidate for the U.S. Congress. Between them, the Gelenbergs have five children.
If you have a question for Dr. Gelenberg, you can send him an email at email@example.com.